Melphalan, S, alkylating agent, Melphalan hydrochloride, refractory multiple myeloma, approved
Leuprolide, S, LHRH agonist, approved
Darolutamide, S, androgen receptor inhibitor, approved
Dexamethasone, S, glucocorticosteroid, approved
Entrectinib, S, NTRK1/2/3 ROS1/ALK kinase inhibitor, NSCLC, approved
Pexidartinib, S, CSF1R/c-KIT/FLT3 kinase inhibitor, TGCT, approved
Gilteritinib, S, FLT3/RTK kinase inhibitor, approved
Duvelisib, S, PI3K δ/ γ kinase inhibitor, approved
Binimetinib, S, MEK1/2 kinase inhibitor, metastatic melanoma, approved
Copanlisib, S, PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase inhibitor, follicular lymphoma, copanlisib_dihydrochloride, approved
Nintedanib, S, triple angiokinase inhibitor, NSCLC, approved
Capmatinib, S, mutant MET kinase inhibitor, NSCLC, approved
Lorlatinib, S, ALK kinase inhibitor, NSCLC, approved
Alpelisib, S, PI3K kinase inhibitor, breast cancer, approved
Zanubrutinib, S, BTK kinase inhibitor, Mantle Cell Lymphoma, approved
Acalabrutinib, S, BTK kinase inhibitor, Mantle Cell Lymphoma, approved
Encorafenib, S, BRAF kinase inhibitor, metastatic melanoma with a BRAF V600E or V600K mutation, approved
Pemigatinib, S, FGFR kinase inhibitor, cholangiocarcinoma, approved
Sirolimus, S, mTOR kinase inhibitor, Lymphangioleiomyomatosis, approved
Plicamycin, S, antineoplastic antibiotic, testicular cancer, approved
Dactinomycin, S, antitumor antibiotic, approved
Tegafur, S, antineoplastic agent, advanced gastric cancer, approved
Raltitrexed, S, antimetabolite, Colorectal cancer, approved
Mercaptopurine, S, Mercaptopurine monohydrate, Antimetabolite, acute lymphatic leukemia, antimetabolite, leukemia, approved
Capecitabine, S, antimetabolite, Colorectal cancer, approved
Fluorouracil, S, antimetabolite, approved
Irinotecan, S, plant alkaloid, Irinotecan_hydrochloride, pancreatic, approved
Leucovorin, S, folate analog, Leucovorin_calcium, approved
Regorafenib, S, multiple kinase inhibitor, Regorafenib_hydrate, approved
Trifluridine, S, antimetabolite, Trifluridine_tipiracil, approved
Axitinib, S, VEGFR 1/2/3 kinase inhibitor, RCC, approved
Cabozantinib, S, tyrosine kinase inhibitor, Cabozantinib_s_malate, approved
Everolimus, S, mTORC1 protein inhibitor, approved
Lenvatinib, S, RTK kinase inhibitor, Lenvatinib_mesylate, approved
Pazopanib, S, multiple protein kinase inhibitor, Pazopanib_hydrochloride, approved
Sorafenib, S, Raf/Mek/Erk kinase inhibitor, AML/RCC/Fast track: HCC, Sorafenib_tosylate, approved
Sunitinib, S, multi-targeted RTK inhibitor, Sunitinib_malate, approved
Temsirolimus, S, mTOR kinase inhibitor, approved
Thiotepa, S, Bladder cancer, approved
Valrubicin, S, approved
Erlotinib, S, EGFR tyrosine kinase inhibitor, FDA, Pancreatic cancer, Erlotinib_hydrochloride, approved
Gemcitabine, S, antimetabolite, Gemcitabine_hydrochloride, approved
Mitomycin, S, antineoplastic antibiotic, approved
Paclitaxel, S, microtubule inhibitor, approved
Carmustine, S, alkylating antineoplastic agent, Glioma, approved
Temozolomide, S, alkylating_agent, approved
Abiraterone, S, adrenal inhibitor, prostate cancer, Abiraterone_acetate, approved
Apalutamide, S, androgen receptor antagonist, approved
Bicalutamide, S, anti-androgen, approved
Cabazitaxel, S, microtubule inhibitor, Cabazitaxel_acetonate, approved
Degarelix, S, gonadotropin-releasing hormone antagonist, approved
Enzalutamide, S, androgen receptor inhibitor, approved
Estradiol, S, Estradiol_valerate, approved
Flutamide, S, anti-androgen, approved
Goserelin, S, LHRH agonist, Goserelin_acetate, approved
Mitoxantrone, S, antitumor antibiotic, Mitoxantrone_hydrochloride, approved
Nilutamide, S, anti-androgen, prostate cancer
Triptorelin, S, GnRH agonist, vet approved, Triptorelin_pamoate, approved
Doxorubicin, S, anthracycline antibiotic, thyroid cancer,Doxorubicin_hydrochloride, approved
Imiquimod, S, immune response modifier, approved
Sonidegib, S, Hedgehok signalling pathway inhibitor, Sonidegib_phosphate, approved
Vismodegib, S, Hedgehok signalling pathway inhibitor, approved
Cobimetinib, S, MAP2K1 inhibitori, Melanoma, Cobimetinib_fumarate, approved
Dabrafenib, S, reversible ATP-competitive kinase inhibitor, Dabrafenib_mesylate, approved
Dacarbazine, S, antineoplastic agent, approved
Hydroxyurea, S, antimetabolite, approved
Trametinib, S, kinase inhibitor, Trametinib_dimethyl_sulfoxide, NSCLC/Melanoma/thyroid, approved
Vemurafenib, S, competitive tyrosine kinase inhibitor, melanoma, approved
Bosutinib, S, Bcr-Abl kinase inhibitor, Chronic myeloid leukemia, Bosutinib_hydrate, approved
Busulfan, S, alkylating agent, CML, approved
Cytarabine, S, antimetabolite, leukemia, approved
Dasatinib, S, kinase inhibitor, leukemia, approved
Imatinib, S, kinase inhibitor, Imatinib_mesylate, approved
Mechlorethamine, S, alkylating agent, Mechlorethamine_hydrochloride, leukemia/Hodgkin's, approved
Nilotinib, S, tyrosine kinase inhibitor, Nilotinib_hydrochloride_hydrate, CML, approved
Ponatinib, S, tyrosine kinase inhibitor, Ponatinib_hydrochloride, CML, approved
Cyclophosphamide, S, AML, approved
Daunorubicin, S, Daunorubicin_hydrochloride, antitumor antibiotic, nonlymphocytic leukemiai, acute lymphocytic leukemia, approved
Enasidenib, S, Enasidenib_mesylate, AML, approved
Idarubicin, S, Idarubicin_hydrochloride, AML, approved
Midostaurin, S, PKC/FLT3 multi kinase inhibitor, AML/ASM/SM-AHN/MCL, approved
Tioguanine, S, acute lymphoblastic leukemia, approved
Tretinoin, S
Vincristine, S, Plant alkaloid, vincristine_sulfate, acute leukaemia, malignant lymphoma, Hodgkin's disease, approved
Etoposide, S, Etoposide_phosphate, testicular/SCLC, approved
Methotrexate, S, Methotrexate_sodium, various cancers, approved
Topotecan, S, Topotecan_hydrochloride, approved
Afatinib, S, Afatinib_dimaleate, NSCLC, approved
Alectinib, S, ALK kinase inhibitor, Alectinib_hydrochloride, approved
Brigatinib, S, ALK/T790M/EGFR kinase inhibitor, approved
Ceritinib, S, ALK kinase inhibitor, approved
Crizotinib, S, NSCLC, approved
Gefitinib, S, NSCLC, approved
Osimertinib, S, Osimertinib_mesylate, NSCLC, approved
Pemetrexed, S, Pemetrexed_Disodium, NSCLC, approved
Vinorelbine, S, Vinorelbine_tartrate, NSCLC, approved
Abemaciclib, S, CDK4/6 inhibitor, Breast cancer, approved
Anastrozole, S, non-steroidal aromatase inhibitor, breast, approved
Epirubicin, S, Epirubicin_hydrochloride, breast, approved
Eribulin, S, microtubule inhibitor, Eribulin_mesylate, breast, liposarcoma, approved
Exemestane, S, aromatase inhibitor, breast, approved
Fulvestrant, S, estrogen receptor downregulator, approved
Ixabepilone, S, microtubule inhibitor, approved
Lapatinib, S, Lapatinib_ditosylate, approved
Letrozole, S, aromatase inhibitor, approved
Neratinib, S, Neratinib_maleate, approved
Olaparib, S, approved
Palbociclib, S, approved
Pamidronate, S, Pamidronate_disodium, approved
Ribociclib, S, approved
Tamoxifen, S, anti-estrogen, Tamoxifen_citrate, approved
Toremifene, S, estrogen receptor antagonist, Toremifene_citrate, approved
Docetaxel, S, microtubule inhibitor, Gastric cancer, approved
Floxuridine, S, antineoplastic, antimetabolite, approved
Alitretinoin, S, Caposhi's sarcoma, approved
Bexarotene, S, FDA, cutaneous T-cell limphoma Off-labeL, lung/breast, approved
Chlorambucil, S, alkylating agent, leukemia/lymphoma/Hodgkin's, approved
Ibrutinib, S, mantle cell lymphoma chronic lymphocytic leukemia, approved
Idelalisib, S, PI3Kδ kinase inhibitor, approved
Lomustine, S, alkylating agent, Brain tumors/Hodgkin's desease, approved
Prednisolone, S, glucocorticosteroid, approved
Ruxolitinib, S, janus-associated kinase inhibitor, bone marrow cancer, approved
Vandetanib, S, kinase inhibitor, medullary thyroid cancer, approved
Bortezomib, S, proteasome inhibitor, relapsed multiple myeloma, approved
Ixazomib, S, proteasome inhibitor, Multiple myeloma, approved
Histrelin, S, Histrelin_acetate, gonadotropin agonist, prostate, approved
Arsenic trioxide, S, AML, approved
Omacetaxine mepesuccinate, S, CML, approved
Megestrol acetate, S, progesterone, Endometrial cancer, Megestrol_acetate, approved
